Literature DB >> 21892025

Imaging of extranodal lymphoma with PET/CT.

Ahmet Turan Ilica1, Kenan Kocacelebi, Recep Savas, Asli Ayan.   

Abstract

Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) represent a spectrum of malignant neoplasms arising from the lymphoid system with an incidence of around 8% of all malignancies. Although they are generally known as tumors of lymph nodes, 25% to 40% of HD/NHL tumors, especially NHL, arise at extranodal sites along the gastrointestinal tract, head and neck, orbit, central and peripheral nervous system, thorax, bone, skin, breast, testis, thyroid, and genitourinary tract. Extranodal involvement is an important pretreatment prognostic factor for patients with lymphoma and its incidence has increased in the past 2 decades. Imaging plays an important role in the noninvasive pretreatment assessment of patients with extranodal lymphoma. This involvement can be subtle and may be overlooked during computed tomography (CT). Positron emission tomography/CT (PET/CT) has evolved into an important imaging tool for evaluation of lymphomas, facilitating the detection of affected extranodal sites even when CT shows subtle or no obvious lesions. Familiarity with extranodal manifestations and suggestive PET/CT features in different sites is important for accurate evaluation of lymphoma. This article reviews the extranodal PET/CT imaging findings regarding HD and NHL.

Entities:  

Mesh:

Year:  2011        PMID: 21892025     DOI: 10.1097/RLU.0b013e31821c99cd

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  13 in total

1.  Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.

Authors:  Özgür Ömür; Yusuf Baran; Aylin Oral; Yeşim Ceylan
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

Review 2.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

3.  Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors.

Authors:  Ka-Hoi Hui; Margaret L Pfeiffer; Bita Esmaeli
Journal:  Saudi J Ophthalmol       Date:  2012-10

Review 4.  Fluorodeoxyglucose uptake in absence of CT abnormality on PET-CT: What is it?

Authors:  Yiyan Liu
Journal:  World J Radiol       Date:  2013-12-28

Review 5.  Thyroid nodule as a first manifestation of Hodgkin lymphoma-report of two cases and literature review.

Authors:  Ewelina Szczepanek-Parulska; Malgorzata Szkudlarek; Przemyslaw Majewski; Jan Breborowicz; Marek Ruchala
Journal:  Diagn Pathol       Date:  2013-07-15       Impact factor: 2.644

6.  Extranodal lymphoma originating in the gluteal muscle with adjacent bone involvement and mimicking a soft tissue sarcoma.

Authors:  Morihiro Katsura; Hirokazu Nishina; Yasushi Shigemori; Takaya Nakanishi
Journal:  Int J Surg Case Rep       Date:  2015-01-15

7.  A Case Report of Primary Extranodal Non-hodgkin Lymphoma First Presentation as a Soft Tissue Swelling Around the Wrist.

Authors:  Alexandra Sopu; Connor Green; Gavin McHugh; John Quinlan
Journal:  J Orthop Case Rep       Date:  2015 Apr-Jun

8.  (18)F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma.

Authors:  Xiao-Feng Li; Qiang Fu; You-Wen Dong; Jian-Jing Liu; Xiu-Yu Song; Dong Dai; Cong Zuo; Wen-Gui Xu
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

9.  Primary extranodal head and neck classical Hodgkin lymphoma: A rare clinical case report.

Authors:  Yongzhi Men; Xuemei Sun; Daolin Wei; Ziwei Yu
Journal:  Exp Ther Med       Date:  2016-05-20       Impact factor: 2.447

10.  Functional Parameters of 18F-FDG PET/CT in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma.

Authors:  Jing Yang; Sha Zhu; Fuwen Pang; Miao Xu; Yiting Dong; Jianqi Hao; Xuelei Ma
Journal:  Contrast Media Mol Imaging       Date:  2018-09-27       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.